Carcinoid Syndrome Diarrhea Treatment Market Size, Share, Industry, Forecast and outlook (2024-2031)

Global Carcinoid Syndrome Diarrhea Treatment Market is segmented By Therapy Type (Chemotherapy, Somatostatin Analog (SSA) Therapy, Others), By Distribution Channel (Retail Pharmacy, Hospital Pharmacy, Online Pharmacy), By End-user (Hospitals, Cancer Research Center, Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031

Carcinoid Syndrome Diarrhea Treatment Market Size

The Global Carcinoid Syndrome Diarrhea Treatment Market reached US$ 3,514.3 million in 2022 and is projected to witness lucrative growth by reaching up to US$ 7,275.6  million by 2031. The global carcinoid syndrome diarrhea treatment market is expected to exhibit a CAGR of 9.8% during the forecast period (2024-2031).  Neuroendocrine tumors (NETs) that release excessive levels of serotonin and other bioactive compounds are known to cause carcinoid syndrome diarrhea (CSD).

Neuroendocrine tumors are uncommon tumors that arise from neuroendocrine cells, which are typically found in the lungs and gastrointestinal system but are present throughout the body.

In order to manage symptoms and enhance the patient's quality of life, carcinoid syndrome diarrhea is often treated with a combination of drugs and supportive care.

Carcinoid Syndrome Diarrhea Treatment Market Scope

To know more Insights Download Sample

Carcinoid Syndrome Diarrhea Treatment Market Dynamics

The Increasing Prevalence Of Neuroendocrine Tumors (NETs) is Driving The Global Carcinoid Syndrome Diarrhea Treatment Market Growth.

The prevalence of neuroendocrine tumors, including those associated with carcinoid syndrome diarrhea, has been rising in recent years. According to the American Cancer Society Report January 2023, annual diagnoses of pancreatic NETs have been increasing over time. This is likely to be partially due to the fact that they are being discovered more frequently by chance during imaging tests like CT or MRI scans of the abdomen that are performed for other purposes. 

More of these tumors are being diagnosed as a result of improvements in the lab's capacity to identify them from other cancers. The average age upon diagnosis for those who have pancreatic NETs is 60. Men are slightly more likely than women to develop these tumors. 

Side Effects Associated With Carcinoid Syndrome Diarrhea Treatment Are Hampering The Global Carcinoid Syndrome Diarrhea Treatment Market Growth.

Side effects associated with carcinoid syndrome diarrhea treatment are a significant challenge for the carcinoid syndrome diarrhea treatment market, posing a threat to the industry's growth and profitability.  For instance,  somatostatin analogs have gastrointestinal side effects, such as nausea, vomiting, stomach pain, bloating, and diarrhea. Gallstones Somatostatin analogs may make certain people more susceptible to developing gallstones.

Carcinoid Syndrome Diarrhea Treatment Market Segment Analysis

The global carcinoid syndrome diarrhea treatment market is segmented based on therapy type, distribution channel, end-user, and region.

The Chemotherapy Segment Is Expected To Hold A Dominant Position In The Market Over The Forecast Period.

The chemotherapy segment accounted for the highest market stake accounting for approximately 3/5th of the carcinoid syndrome diarrhea treatment market in 2022.  The majority of chemotherapy drugs target rapidly dividing cells, and when these cells are affected in the gastrointestinal tract, various symptoms might result. 

Some chemotherapeutic medications used to treat NETs linked to CSD include advanced pancreatic neuroendocrine tumors are routinely treated with streptozocin in combination with other chemotherapy medicines, such as 5-fluorouracil (5-FU). For the treatment of advanced NETs, including those associated with CSD, temozolomide is an oral chemotherapeutic medicine that may be used with other medications.

Carcinoid Syndrome Diarrhea Treatment Market Geographical Share

North America Holds A Dominant Position In The Global Carcinoid Syndrome Diarrhea Treatment Market.

North America is estimated to hold around 41.2% of the total market share throughout the forecast period. The increasing aging population in the region creating a need for specialized carcinoid syndrome diarrhea treatment and collaborations by the market players are the factors expected to boost the regional growth over the forecast period.

More than 12,000 Americans receive a NET diagnosis each year, and over 171,000 of them are now living with the condition. This growth is believed to be a result of advancements in NET diagnoses, such as improved imaging tests and endoscopy, as well as greater patient awareness of these tumors. 

Carcinoid Syndrome Diarrhea Treatment Companies

The major global players in the market include Novartis AG, Lexicon Pharmaceuticals, Ipsen Biopharmaceuticals, Pfizer Inc., Hutchison China MediTech Limited (Chi-Med), Progenics Pharmaceuticals, Ipsen Pharma, Teva Pharmaceutical Industries Ltd., Helsinn Group, and Omega Laboratories Ltd. among others. 

COVID-19 Impact on Carcinoid Syndrome Diarrhea Treatment Market

Russia Ukraine Conflict Analysis

The Russia-Ukraine war may affect the carcinoid syndrome diarrhea treatment market due to consumer confidence and limited access to healthcare facilities being impacted during times of geopolitical instability and economic uncertainty. 

Conflicts can lead to population relocation and mobility restrictions, which makes it challenging for patients to get specialized care, including consultations with medical specialists skilled in controlling CSD. This restriction may affect a person with CSD's ability to receive a prompt diagnosis, treatment planning, and follow-up care.

Artificial Intelligence Analysis:

Artificial intelligence (AI) is increasingly being used in the carcinoid syndrome diarrhea treatment market to improve various aspects of the customer experience. Medical professionals can choose the best CSD treatment options with the help of AI-based tools. AI algorithms can offer therapy suggestions based on evidence-based guidelines, clinical trials, and real-world data by analyzing patient-specific data, such as tumor features, biomarker levels, and patient history. Planning a patient's treatment in this way can help to maximize their results.

Key Developments

• In December 2022, TerSera Therapeutics declared a new sponsorship with the Carcinoid Cancer Foundation (CCF) and Alira Health to amplify and improve a holistic patient journey digital platform for patients with neuroendocrine tumors and carcinoid syndrome.

Why Purchase the Report?

• To visualize the global carcinoid syndrome diarrhea treatment market segmentation based on the therapy type, distribution channel, end-user, and region and understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development. 
• Excel data sheet with numerous data points of carcinoid syndrome diarrhea treatment market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.

The global carcinoid syndrome diarrhea treatment market report would provide approximately 61 tables, 57 figures, and 195 Pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies